Abstract
The aim of this study is to evaluate tumor necrosis factor (TNF) inhibitor persistence and the impact of comorbidity on treatment persistence in patients with rheumatoid arthritis (RA). In a Korean National Health Insurance claims database, patients with a diagnosis code of RA (M05 or M06) who started TNF inhibitor therapy between July 1, 2007 and June 30, 2008 were enrolled. The study cohort was followed until December 31, 2009. Persistence was examined using Kaplan–Meier survival analysis, and multivariate Cox proportional hazard models were developed to examine the potential impact of comorbidities on drug persistence. A total of 388 patients were enrolled in the study cohort. The mean persistence rate in the overall population was 61% at 18 months. Drug survival rates for adalimumab and etanercept at 6 months were 82 and 85%, respectively, and 73 and 78%, respectively, at 12 months. Charlson comorbidity index (CCI) scores and comorbidities such as diabetes, chronic pulmonary disease, mild liver disease, and depression at initiation were not related with drug persistence, while peptic ulcer disease (PUD) lowered the risk of discontinuation of TNF inhibitors (HR 0.73, 95% CI 0.55–0.97). Old age (HR 1.59, 95% CI 1.09–2.33) and prescription of inhibitors by an internist (HR 1.59, 95% CI 1.02–2.48) were associated with discontinuation of TNF inhibitors. The persistence of TNF inhibitors was 61% at 18 months. CCI score and other comorbidities were not related with early discontinuation of TNF inhibitors, while PUD was an independent contributing factor to TNF inhibitor persistence.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kievit W, Fransen J, Adang EM et al (2011) Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatol (Oxf) 50:196–203
Lipsky PE, van der Heijde DM, St Clair EW et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343:1594–1602
Moreland LW, Schiff MH, Baumgartner SW et al (1999) Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130:478–486
Weinblatt ME, Keystone EC, Furst DE et al (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48:35–45
Flendrie M, Creemers MCW, Welsing PMJ, den Broeder AA, van Riel PLCM (2003) Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis Ann Rheum Dis 62(Suppl II):ii30–ii33
Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE (2002) Predictors of infection in rheumatoid arthritis. Arthritis Rheum 46:2294–2300
Sikka R, Xia F, Aubert RE (2005) Estimating medication persistence using administrative claims data. Am J Manag Care 11:449–457
Tang B, Rahman M, Waters HC, Callegari P (2008) Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther 30:1375–1384
National Health Insurance Corporation. National Health Insurance Statistics: The first half of 2008. [Cited 2009Mar 2]. Available from: http://www.nhic.or.kr
Quan H, Sundararajan V, Halfon P et al (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130–1139
Carmona L, Gomez-Reino JJ (2006) Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 8:R72
Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Deborah PM (2009) Symmons for the British Society for Rheumatology Biologics Register. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 11:R52
Duclos M, Gossec L, Ruyssen-Witrand A et al (2006) Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. J Rheumatol 33:2433–2438
Gabriel SE, Michaud K (2009) Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 11:229
Wolfe F, Michaud K (2008) The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. Arthritis Rheum 58:2612–2621
Gomez-Reino JJ, Carmona L (2006) Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 8:R29
Kristensen LE, Gulfe A, Saxne T, Geborek P (2008) Efficacy and tolerability of anti-tumor necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group. Ann Rheum Dis 67:364–369
Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL, on behalf of the British Society for Rheumatology Biologics Register (2011) Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology. Biologics Register. Ann Rheum Dis 70: 583–589
Heiberg MS, Koldingsnes W, Mikkelsen K et al (2008) The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 59:234–240
Dezii CM (2001) Persistence with drug therapy: a practical approach using administrative claims data. Manag care 10:42–45
Acknowledgments
This study was supported by the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (A102065).
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cho, SK., Sung, YK., Choi, CB. et al. Impact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: an analysis of Korean National Health Insurance claims data. Rheumatol Int 32, 3851–3856 (2012). https://doi.org/10.1007/s00296-011-2312-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-011-2312-1